Spots Global Cancer Trial Database for capox
Every month we try and update this database with for capox cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Total Neoadjuvant Therapy of SCRT+CAPOX vs SCRT+CAPOXIRI for Locally Advanced Rectal Cancer (ENSEMBLE) | NCT05646511 | Locally Advance... | SCRT CAPOX CAPOXIRI | 18 Years - | National Cancer Center Hospital East | |
| Immunoscore as Decision Guidance for Adjuvant Chemotherapy in Colon Cancer | NCT04488159 | Colon Cancer St... | Capecitabine Oxaliplatin Fluorouracil Leucovorin Immunoscore® as... Physical exerci... | 18 Years - 100 Years | Medical University of Vienna | |
| Immunoscore as Decision Guidance for Adjuvant Chemotherapy in Colon Cancer | NCT04488159 | Colon Cancer St... | Capecitabine Oxaliplatin Fluorouracil Leucovorin Immunoscore® as... Physical exerci... | 18 Years - 100 Years | Medical University of Vienna | |
| Node-sparing Radiotherapy Combined With Total Neoadjuvant CAPOX and Sintilimab for MSS Middle and Low Rectal Cancer | NCT06204094 | Locally Advance... | node-sparing sh... Sintilimab Capecitabine Oxaliplatin TME surgery watch and wait | 18 Years - 75 Years | Jinhua Central Hospital | |
| Organ Preservation Following Enverolimab-based Total Neoadjuvant Therapy for Locally Advanced Very Low Rectal Cancer | NCT05969847 | Rectal Cancer | split-course hy... CAPOX Envafolimab Local excision | 18 Years - 75 Years | Fujian Medical University Union Hospital | |
| Preoperative Radiotherapy And ASTX660 in Rectum Cancer | NCT05912075 | Locally-advance... | mFOLFIRINOX Pelvic radiothe... Capecitabine TOLINAPANT (AST... Pelvic radiothe... FOLFOX4 CAPOX | 18 Years - | Gustave Roussy, Cancer Campus, Grand Paris | |
| Combination Chemotherapy for 3 Months or 6 Months in Treating Patients With Stage III Colon Cancer | NCT00958737 | Colorectal Canc... | FOLFOX regimen CAPOX | 18 Years - | GERCOR - Multidisciplinary Oncology Cooperative Group | |
| CAPOX in KRAS Wild-Type Advanced Adenocarcinoma of the Small Bowel or Ampulla of Vater | NCT01202409 | Gastrointestina... | Panitumumab | 18 Years - | M.D. Anderson Cancer Center | |
| Conversion Therapy With Sintilimab Plus CAPOX in Patients With Unresectable Locally Advanced or Limited Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction | NCT04263870 | Gastroesophagea... Stomach Adenoca... Locally Advance... Metastatic Gast... | sintilimab | 18 Years - 75 Years | Sichuan University | |
| MRI Simulation-guided Boost in Short-course Preoperative Radiotherapy for Unresectable Rectal Cancer | NCT03714490 | Rectal Neoplasm... | SCPRT CRT CAPOX | 18 Years - 70 Years | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | |
| Preoperative Radiotherapy And ASTX660 in Rectum Cancer | NCT05912075 | Locally-advance... | mFOLFIRINOX Pelvic radiothe... Capecitabine TOLINAPANT (AST... Pelvic radiothe... FOLFOX4 CAPOX | 18 Years - | Gustave Roussy, Cancer Campus, Grand Paris | |
| NEO: Neoadjuvant Chemotherapy, Excision and Observation for Early Rectal Cancer | NCT03259035 | Rectal Cancer | Folfox Protocol Capox | 18 Years - | Canadian Cancer Trials Group | |
| Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease | NCT05174169 | Stage III Colon... | Signatera test mFOLFOX6 3-6 mo... CAPOX 3 month mFOLFIRINOX mFOLFOX6 6 mont... CAPOX 6 month | 18 Years - | NRG Oncology | |
| Post-surgical Liquid Biopsy-guided Treatment of Stage III and High-risk Stage II Colon Cancer Patients: the PEGASUS Trial | NCT04259944 | Colon Cancer | CAPOX Capecitabine FOLFIRI | 18 Years - | IFOM ETS - The AIRC Institute of Molecular Oncology | |
| Azacitidine and CAPOX in Metastatic Colorectal Cancer | NCT01193517 | Colorectal Canc... | Azacitidine Capecitabine Oxaliplatin Azacitidine MTD | 18 Years - | M.D. Anderson Cancer Center | |
| A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC) | NCT05849480 | Biliary Cancer Bile Duct Cance... Cancer of the B... | oxaliplatin capecitabine Keytruda CDX-1140 | 18 Years - 120 Years | National Institutes of Health Clinical Center (CC) | |
| Post-surgical Liquid Biopsy-guided Treatment of Stage III and High-risk Stage II Colon Cancer Patients: the PEGASUS Trial | NCT04259944 | Colon Cancer | CAPOX Capecitabine FOLFIRI | 18 Years - | IFOM ETS - The AIRC Institute of Molecular Oncology | |
| A Study Evaluating Bemarituzumab in Combination With Other Anti-cancer Therapies in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer. | NCT05322577 | Gastric Cancer Gastroesophagea... | Bemarituzumab CAPOX SOX Nivolumab | 18 Years - 100 Years | Amgen | |
| A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC) | NCT05849480 | Biliary Cancer Bile Duct Cance... Cancer of the B... | oxaliplatin capecitabine Keytruda CDX-1140 | 18 Years - 120 Years | National Institutes of Health Clinical Center (CC) | |
| A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers | NCT05152147 | Gastric Neoplas... Gastroesophagea... Esophageal Aden... | Zanidatamab Tislelizumab Trastuzumab Capecitabine Oxaliplatin Cisplatin 5-Fluorouracil | 18 Years - | Jazz Pharmaceuticals | |
| Concomitant Intraperitoneal and Systemic Chemotherapy in Patients With Extensive Peritoneal Carcinomatosis of Gastric Origin | NCT05379790 | Gastric Cancer Peritoneal Meta... | Irinotecan CAPOX | 18 Years - | Erasmus Medical Center | |
| Chemotherapy and Pembrolizumab, Followed by Pembrolizumab and Olaparib as Firstline Therapy in Her-2 Negative Gastric/GEJ Adenocarcinoma | NCT05268510 | Esophagogastric... | Pembrolizumab Olaparib mFOLFOX-6 CapOX | 18 Years - | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
